Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 8/20 | 1.00 |
| ▸ | GRM2 | Q14416 | 4/20 | 1.00 |
| ▸ | GRM3 | Q14832 | 4/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 4/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 4/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 3/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 1.00 |
| ▸ | GRM8 | O00222 | 2/20 | 1.00 |
| ▸ | GRM6 | O15303 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | GRM5 | P41594 | 1/20 | 1.00 |
| ▸ | MTOR | P42345 | 1/20 | 1.00 |
| ▸ | GRM1 | Q13255 | 1/20 | 1.00 |
| ▸ | PLCB1 | Q9NQ66 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.68 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3125919 | 1.00 | GRM4 (1.00) | GRM4GRM2GRM3CYP1A2CYP2C19 | |
| SCHEMBL935371 | 1.00 | GRM4 (1.00) | GRM4GRM2GRM3CYP1A2CYP2C19 | |
| SCHEMBL481144 | 1.00 | GRM4 (1.00) | GRM4GRM2GRM3CYP1A2CYP2C19 | |
| SCHEMBL719389 | 1.00 | GRM4 (1.00) | GRM4GRM2GRM3CYP1A2CYP2C19 | |
| SCHEMBL2157698 | 1.00 | GRM4 (1.00) | GRM4GRM2GRM3CYP1A2CYP2C19 | |
| SCHEMBL179741 | 1.00 | GRM4 (1.00) | GRM4GRM2GRM3CYP1A2CYP2C19 | |
| SCHEMBL235442 | 1.00 | GRM4 (1.00) | GRM4GRM2GRM3CYP1A2CYP2C19 | |
| SCHEMBL2916853 | 0.88 | GRM4 (0.78) | GRM4GRM2GRM3CYP1A2CYP2C19 | |
| SCHEMBL4835681 | 0.88 | GRM4 (0.78) | GRM4GRM2GRM3CYP1A2CYP2C19 | |
| SCHEMBL7271016 | 0.88 | GRM4 (0.78) | GRM4GRM2GRM3CYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11938106-B2 | Treatment of tinnitus using glutamate receptor agonists | NORTHEAST OHIO MEDICAL UNIVERSITY (US) | 2024-03-26 | — | — | US | claimed |
| US-20230038631-A1 | TREATMENT OF TINNITUS USING GLUTAMATE RECEPTOR AGONISTS | NORTHEAST OHIO MEDICAL UNIV (US) | 2023-02-09 | — | — | US | claimed |
| US-11304917-B2 | Treatment of tinnitus using glutamate receptor agonists | NORTHEAST OHIO MEDICAL UNIVERSITY (US) | 2022-04-19 | — | — | US | claimed |
| US-20260137689-A1 | INTEGRATION OF MOLECULAR MECHANISMS IN THE STRIATUM AS A COMBINATION DRUG STRATEGY FOR THE TREATMENT OF PSYCHIATRIC AND NEUROLOGICAL DISORDERS IN WHICH ANHEDONIA OR MOTIVATION-RELATED DYSFUNCTION EXISTS | ALTO NEUROSCIENCE INC (US) | 2026-05-21 | — | — | US | disclosed |
| EP-3157408-B1 | DEVICES TO PROVIDE HANDS FREE SCLERAL DEPRESSION DURING OPHTHALMIC PROCEDURES | ALCON INC (CH) | 2026-03-25 | — | — | EP | disclosed |
| EP-4714407-A2 | DEVICES TO PROVIDE HANDS FREE SCLERAL DEPRESSION DURING OPHTHALMIC PROCEDURES | Alcon Inc. (CH) | 2026-03-25 | — | — | EP | disclosed |
| US-20250099404-A1 | TRANS-4-HYDROXYCYCLOHEXYL PHENYL AMIDE MITOFUSIN ACTIVATORS AND METHODS OF USE THEREOF | MITOCHONDRIA IN MOTION, INC. (US) | 2025-03-27 | — | — | US | disclosed |
| US-20250057694-A1 | DEVICES AND METHODS TO PROVIDE HANDS FREE SCLERAL DEPRESSION AND ILLUMINATION DURING OPHTHALMIC PROCEDURES | Ganihand, LLC (US) | 2025-02-20 | — | — | US | disclosed |
| WO-2025022003-A1 | BETA-PEPTIDES WITH CYTOTOXIC ACTIVITY ON CANCER CELLS | Universität Linz (AT) | 2025-01-30 | — | — | WO | disclosed |
| US-12059404-B2 | Mesembrenol and/or mesembranol for prophylaxis and treatment of patients suffering from epilepsy and associated diseases | HG&H PHARMACEUTICALS (PTY) LTD (ZA) | 2024-08-13 | — | — | US | disclosed |
| US-11938106-B2 | Treatment of tinnitus using glutamate receptor agonists | NORTHEAST OHIO MEDICAL UNIVERSITY (US) | 2024-03-26 | — | — | US | disclosed |
| US-20060287280-A1 | Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of PHEX | ENOBIA PHARMA (CA) | 2006-12-21 | — | — | US | disclosed |
| US-20060135480-A1 | Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex | ENOBIA PHARMA (CA) | 2006-06-22 | — | — | US | disclosed |
| EP-0711755-B1 | Pyrrolidinyl di-carboxylic acid derivatives as metabotropic glutamate receptor antagonists | LILLY CO ELI (US) | 2000-05-31 | — | — | EP | disclosed |
| US-6013672-A | ADMINISTERING TO AN INDIVIDUAL SUFFERING FROM HEAD, SPINAL CORD TRAUMA, STROKE AND EPILEPSY A THERAPEUTICALLY EFFECTIVE DOSE OF A METABOTROPIC GLUTAMATE RECEPTOR AGONIST | UAB RESEARCH FOUNDATION (US) | 2000-01-11 | — | — | US | disclosed |
| US-5622981-A | Use of metabotropic receptor agonists in progressive neurodegenerative diseases | CORTEX PHARMACEUTICALS, INC. (US) | 1997-04-22 | — | — | US | disclosed |
| WO-1996015108-A1 | PYRROLIDINYL DI-CARBOXYLIC ACID DERIVATIVES AS METABOTROPIC GLUTAMATE RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 1996-05-23 | — | — | WO | disclosed |
| EP-0711755-A1 | Pyrrolidinyl di-carboxylic acid derivatives as metabotropic glutamate receptor antagonists | ELI LILLY AND COMPANY (US) | 1996-05-15 | — | — | EP | disclosed |
| EP-0703218-A1 | Pyrrolidinyl di-carboxylic acid derivatives as metabotropic glutamate receptor antagonists | ELI LILLY AND COMPANY (US) | 1996-03-27 | — | — | EP | disclosed |
| US-5473077-A | 4-aminopyrrolidine-2,4-substitude independently with carboxylic acid or 5-tetrazolyl for treating nervous system disorders and psychological disorders | ELI LILLY AND COMPANY (US) | 1995-12-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260137689-A1 | INTEGRATION OF MOLECULAR MECHANISMS IN THE STRIATUM AS A COMBINATION DRUG STRATEGY FOR THE TREATMENT OF PSYCHIATRIC AND NEUROLOGICAL DISORDERS IN WHICH ANHEDONIA OR MOTIVATION-RELATED DYSFUNCTION EXISTS | CHRNA5, CHRNA2, CHRNA4 | GRM4 47/4885GRM2 31/4885GRM3 60/4885 |
| US-12059404-B2 | Mesembrenol and/or mesembranol for prophylaxis and treatment of patients suffering from epilepsy and associated diseases | GRM3, GRM2, GRIN3A | GRM4 12/4885GRM2 2/4885GRM3 1/4885 |
| US-20060287280-A1 | Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of PHEX | GLS, SUCNR1, PGD | GRM4 1241/4885GRM2 899/4885GRM3 1602/4885 |
| US-20060135480-A1 | Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex | GLS, SUCNR1, GCDH | GRM4 1196/4885GRM2 871/4885GRM3 1656/4885 |
| US-20250099404-A1 | TRANS-4-HYDROXYCYCLOHEXYL PHENYL AMIDE MITOFUSIN ACTIVATORS AND METHODS OF USE THEREOF | MFN2, TFB2M, HADHA | GRM4 3230/4885GRM2 1967/4885GRM3 3829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.